Wall Street brokerages forecast that Stemline Therapeutics Inc (NASDAQ:STML) will announce earnings per share of ($0.71) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Stemline Therapeutics’ earnings. The highest EPS estimate is ($0.67) and the lowest is ($0.85). Stemline Therapeutics reported earnings per share of ($0.93) during the same quarter last year, which indicates a positive year over year growth rate of 23.7%. The company is scheduled to report its next earnings report on Friday, March 15th.
On average, analysts expect that Stemline Therapeutics will report full-year earnings of ($2.80) per share for the current year, with EPS estimates ranging from ($2.93) to ($2.74). For the next financial year, analysts expect that the firm will report earnings of ($1.31) per share, with EPS estimates ranging from ($2.62) to $1.52. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that follow Stemline Therapeutics.
Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.73) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.06).
Several equities research analysts recently commented on STML shares. Roth Capital set a $33.00 price target on Stemline Therapeutics and gave the company a “buy” rating in a research note on Wednesday, November 14th. BidaskClub cut Stemline Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 2nd. HC Wainwright set a $38.00 price target on Stemline Therapeutics and gave the company a “buy” rating in a research note on Monday, November 12th. ValuEngine cut Stemline Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, November 10th. Finally, Zacks Investment Research raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 16th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $26.32.
Shares of NASDAQ STML opened at $10.47 on Monday. The company has a market capitalization of $332.95 million, a P/E ratio of -3.56 and a beta of 0.64. Stemline Therapeutics has a 52 week low of $10.00 and a 52 week high of $20.55.
In related news, COO Kenneth Hoberman sold 26,296 shares of the business’s stock in a transaction that occurred on Monday, November 26th. The stock was sold at an average price of $11.85, for a total value of $311,607.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 14.80% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in STML. BlackRock Inc. increased its position in shares of Stemline Therapeutics by 17.9% during the second quarter. BlackRock Inc. now owns 1,852,820 shares of the biopharmaceutical company’s stock valued at $29,739,000 after purchasing an additional 281,394 shares during the period. Millennium Management LLC increased its position in shares of Stemline Therapeutics by 169.3% during the second quarter. Millennium Management LLC now owns 161,735 shares of the biopharmaceutical company’s stock valued at $2,596,000 after purchasing an additional 101,679 shares during the period. Point72 Asset Management L.P. increased its position in shares of Stemline Therapeutics by 20.9% during the third quarter. Point72 Asset Management L.P. now owns 260,000 shares of the biopharmaceutical company’s stock valued at $4,316,000 after purchasing an additional 45,000 shares during the period. C WorldWide Group Holding A S increased its position in shares of Stemline Therapeutics by 25.7% during the second quarter. C WorldWide Group Holding A S now owns 213,706 shares of the biopharmaceutical company’s stock valued at $3,430,000 after purchasing an additional 43,711 shares during the period. Finally, Northern Trust Corp increased its position in shares of Stemline Therapeutics by 12.5% during the second quarter. Northern Trust Corp now owns 380,378 shares of the biopharmaceutical company’s stock valued at $6,106,000 after purchasing an additional 42,262 shares during the period. Institutional investors and hedge funds own 64.20% of the company’s stock.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.
Further Reading: Diversification Important in Investing
Get a free copy of the Zacks research report on Stemline Therapeutics (STML)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.